Bill Berkrot
Recent Stories By Bill Berkrot:
-
Pfizer's new tax rate higher than investors hoped, shares fall January 30, 2018
(Reuters) - Pfizer Inc said on Tuesday it expected to pay tax at an adjusted rate of about 17 percent this year, higher than some investors had expected, sending its shares down more than 3 percent....
-
Exclusive: J&J out of race for Pfizer's $20 billion consumer unit as deadline loomsJanuary 25, 2018
LONDON/NEW YORK/FRANKFURT (Reuters) - Johnson & Johnson has pulled out of the race to buy Pfizer's consumer health business, leaving GlaxoSmithKline and Reckitt Benckiser among those...
-
Spark's price for Luxturna blindness gene therapy too high: ICERJanuary 12, 2018
(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that...
-
GSK CEO says looking at Pfizer consumer business, but not a priorityJanuary 9, 2018
(Reuters) - GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.Pfizer...
-
Tiny stem cell companies close in on major heart disease goalsDecember 18, 2017
NEW YORK (Reuters) - The early hope that stem cell therapy would make the paralyzed walk, the blind see and cure diabetes have given way to a long list of failures, highlighted by early stem cell...
-
Pfizer breast cancer drug superior to chemotherapy in late stage studyDecember 8, 2017
(Reuters) - Patients with advanced breast cancer tied to an inherited gene mutation who were treated with an experimental Pfizer Inc drug went about three months longer before their disease worsened...
-
Exclusive: CVS eyes major expansion of health clinics with Aetna deal - sourcesDecember 1, 2017
NEW YORK (Reuters) - CVS Health Corp is planning to significantly expand health services at its retail pharmacies if it completes a more than $66 billion deal for insurer Aetna Inc , a move that...
-
Pfizer expects broad interest for consumer health businessOctober 31, 2017
NEW YORK (Reuters) - Pfizer Inc, the largest U.S. drugmaker, expects no shortage of suitors for its consumer health business and said it would decide whether to sell, spin off or retain the unit next...
-
Celgene cuts 2020 outlook, Otezla sales disappoint; shares plungeOctober 26, 2017
(Reuters) - Celgene Corp on Thursday reported third-quarter sales of its key psoriasis drug Otezla that badly missed expectations and significantly scaled down its 2020 targets for product sales and...
-
Amgen quarterly profit tops expectations despite sales declineOctober 25, 2017
(Reuters) - Amgen Inc reported higher-than-expected third quarter profit on Wednesday as lower costs and improved operating margins helped offset sales declines in some of its most important...
-
Pfizer delays major M&A as it awaits U.S. tax reform clarity August 1, 2017
(Reuters) - Pfizer Inc's chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any...
-
Many treatment options, most experimental, available to John McCain July 20, 2017
NEW YORK (Reuters) - There is at least one approved device and scores of experimental treatments being tested that could improve the odds of longer-term survival for patients with the type of...